ClinicalTrials.gg

Program

pomalidomide

Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.

Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.

Furthest: phase 4, since Jul 15, 201037 company-led studies, 2 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb251 open or runningphase 3since Jul 15, 2010Nov 7, 2003Jan 10, 2027phase 3 · NCT05519085
Oncotherapeutics40 open or runningphase 2since Feb 20, 2012Feb 20, 2012none ahead
Amgen20 open or runningphase 2since Nov 22, 2019Oct 18, 2016none ahead
Simcere Pharmaceutical Group20 open or runningphase 3since Sep 24, 2016Sep 24, 2016none ahead
criterium-inc10 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Knight Therapeutics (USA)10 open or runningphase 1since Jul 3, 2026Jul 3, 2026none ahead
megalabs11 open or runningphase 1since Sep 15, 2023Sep 15, 2023none ahead
Takeda10 open or runningphase 4since Dec 20, 2021Dec 20, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Nov 7, 2003.

  1. Dec 10, 20132 phase 2 studies in Multiple MyelomaBristol-Myers Squibb · NCT02011113, NCT02045017
  2. Jun 18, 2014Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02168205 · 55 enrolled · United States
  3. Jul 7, 20142 phase 2 studies in Multiple MyelomaOncotherapeutics · NCT02188368, NCT02206425
  4. Sep 24, 2016Simcere Pharmaceutical Group's first study: phase 3 study in Multiple MyelomaNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT02916420 · 73 enrolled · China
  5. Oct 18, 2016Amgen's first study: phase 1 study in RecurrenceNew to AmgenAmgen · NCT02939183 · 61 enrolled · United States, Australia, Canada and more
  6. Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
  7. Aug 18, 2017Phase 2 study in Central Nervous System NeoplasmsBristol-Myers Squibb · NCT03257631 · 53 enrolled · United States, France, Italy and more
  8. Dec 14, 2017Phase 1 study in Multiple MyelomaSimcere Pharmaceutical Group · NCT03424928 · 12 enrolled · China
  9. Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
  10. Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
  11. Dec 20, 2021Takeda's first study: phase 4 study in Multiple MyelomaNew to TakedaTakeda · NCT05183139
  12. Aug 25, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085 · 810 planned · United States, Argentina, Australia and more
  13. Sep 15, 2023megalabs's first study: phase 1 study in Bioequivalence StudyNew to megalabsmegalabs · NCT06058689 · 10 planned · India
  14. Jul 3, 2026Knight Therapeutics (USA)'s first study: phase 1 study in Pomalidomide Bioequivalence Study in Healthy VolunteersNew to Knight Therapeutics (USA)Knight Therapeutics (USA) · NCT07694011 · 34 enrolled · Chile

Ahead

  1. Jan 10, 2027Primary completion: phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07694011Pomalidomide Bioequivalence Study in Healthy Volunteers · Chile1CompletedKnight Therapeutics (USA)Feb 5, 202534
NCT06058689Bioequivalence Study · India1Not yet recruitingmegalabsNov 15, 202410
NCT05519085Recurrence · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbJan 10, 2027810
NCT05183139Multiple Myeloma4WithdrawnTakedaDec 31, 20260
NCT04191616Recurrence · United States, Denmark, Estonia and more2CompletedAmgenNov 30, 202254
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedBristol-Myers SquibbApr 13, 2026386
NCT03424928Multiple Myeloma · China1CompletedSimcere Pharmaceutical GroupJan 29, 201812
NCT03257631Central Nervous System Neoplasms · United States, France, Italy and more2CompletedBristol-Myers SquibbSep 14, 202353
NCT03104270Multiple Myeloma · United States2TerminatedOncotherapeuticsOct 25, 201913
NCT02939183Recurrence · United States, Australia, Canada and more1CompletedAmgenOct 6, 202261
NCT02916420Multiple Myeloma · China3UNKNOWNSimcere Pharmaceutical GroupJun 201873
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02188368Multiple Myeloma · United States2TerminatedOncotherapeuticsOct 23, 202045
NCT02168205Healthy Volunteers · United States1CompletedBristol-Myers SquibbSep 19, 201455
NCT02045017Multiple Myeloma · Austria, France, Germany and more2CompletedBristol-Myers SquibbJan 27, 201781
NCT02011113Multiple Myeloma · Japan2CompletedBristol-Myers SquibbSep 201436
NCT01986894Clinical Pharmacology, Healthy Volunteer Study · United States1CompletedBristol-Myers SquibbDec 2, 201372
NCT01946477Multiple Myeloma · United States, Canada, Japan and more2CompletedBristol-Myers SquibbApr 30, 2025186
NCT01835561Liver Diseases · United States1CompletedBristol-Myers SquibbAug 16, 201432
NCT01734928Multiple Myeloma · United States, Austria, Canada and more3CompletedBristol-Myers SquibbMay 9, 2022559
NCT01712789Multiple Myeloma · Austria, Belgium, Denmark and more3CompletedBristol-Myers SquibbDec 11, 2019682
NCT01707407Pharmacology, Clinical · United States1CompletedBristol-Myers SquibbNov 1, 201232
NCT01568294Multiple Myeloma · Japan1CompletedBristol-Myers SquibbJul 8, 201512
NCT01559129Scleroderma, Systemic · United States, Australia, France and more2TerminatedBristol-Myers SquibbNov 3, 201623
NCT01541332Multiple Myeloma · United States2UNKNOWNOncotherapeuticsDec 201670
NCT01522547Anemia, Sickle Cell · United States1CompletedBristol-Myers SquibbOct 1, 201212
NCT01497093Multiple Myeloma · United States1CompletedBristol-Myers SquibbJul 23, 201934
NCT01474330Healthy · United States1CompletedBristol-Myers SquibbOct 1, 201133
NCT01464034Multiple Myeloma · United States2Terminatedcriterium-incJul 2020136
NCT01324947Multiple Myeloma · Australia, Belgium, Canada and more3CompletedBristol-Myers SquibbJul 31, 201474
NCT01311687Multiple Myeloma · United States, Australia, Belgium and more3CompletedBristol-Myers SquibbMar 1, 2013455
NCT01178281Primary Myelofibrosis · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJan 1, 2013267
NCT00833833Multiple Myeloma · United States, Canada2CompletedBristol-Myers SquibbApr 2011259
NCT00717522Sarcoma · United States2TerminatedBristol-Myers SquibbJan 1, 20097
NCT00537511Carcinoma, Small Cell · United States, Canada2TerminatedBristol-Myers SquibbNov 1, 201022
NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more2CompletedBristol-Myers SquibbMay 1, 200988
NCT00072722Prostatic Neoplasms · United States2CompletedBristol-Myers Squibb36

How it is read

Names in the registry

  • “Pomalidomide”, 41 entries
  • “pomalidomide”, 4 entries
  • “Pomalidomide 4 MG Oral Capsule”, 2 entries
  • “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
  • “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry

Codes read as this program: CC4047.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.